A randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of tegaserod in patients from China with chronic constipation

World Journal of Gastroenterology

Volumn 13, Issue 5, 2007, Pages 732-739

  Lin, San Ren ^a   Ke, Mei Yun ^b   Luo, Jin Yan ^c   Yuan, Yao Zong ^d   Wang, Ji Yao ^e   diTommaso, Shelley ^f   Walter, Verena ^f   Huang, Jiaqing ^a,f  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c XI'AN JIAOTONG UNIVERSITY   (China)

^d SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^e ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^f NOVARTIS PHARMA AG   (Switzerland)

Author keywords

China; Chronic constipation; Complete spontaneous bowel movement; Placebo controlled; Stool; Tegaserod

Indexed keywords

PLACEBO; TEGASEROD;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CHINA; CHRONIC DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; FEMALE; HUMAN; HYPERTENSION; INCIDENCE; ISCHEMIC COLITIS; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYMPTOM; TINNITUS; URINARY TRACT INFLAMMATION; VEIN THROMBOSIS; VERTIGO;

EID: 33847002358     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i5.732     Document Type: Article

References (21)

1. Cheng C, Chan AO, Hui WM, Lam SK. Coping strategies, illness perception, anxiety and depression of patients with idiopathic constipation: a population-based study. Aliment Pharmacol Ther 2003; 18: 319-326
2. Brandt LJ, Prather CM, Quigley EM, Schiller LR, Schoenfeld P, Talley NJ. Systematic review on the management of chronic constipation in North America. Am J Gastroenterol 2005; 100 Suppl 1: S5-S21
3. Garrigues V, Galvez C, Ortiz V, Ponce M, Nos P, Ponce J. Prevalence of constipation: agreement among several criteria and evaluation of the diagnostic accuracy of qualifying symptoms and self-reported definition in a population-based survey in Spain. Am J Epidemiol 2004; 159: 520-526
4. Guo XK, Pan MY, Han G, Fang S, Lu XC, Guo H. A cluster, stratified, randomized epidemiologic survey and analysis of related factors on adult chronic constipation in Beijing area. Chin J Dig 2002; 22: 637-638
5. Lembo A, Camilleri M. Chronic constipation. N Engl J Med 2003; 349: 1360-1368
6. Norton C. Constipation in older patients: effects on quality of life. Br J Nurs 2006; 15: 188-192
7. Wald A. Pathophysiology, diagnosis and current management of chronic constipation. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 90-100
8. Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead W. Rome II. The Functional Gastrointestinal Disorders. 2nd ed. McLean, VA: Degnon Associates, 2000
9. Xing JH, Soffer EE. Adverse effects of laxatives. Dis Colon Rectum 2001; 44: 1201-1209
10. Ramkumar D, Rao SS. Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. Am J Gastroenterol 2005; 100: 936-971
11. Schiller LR. New and emerging treatment options for chronic constipation. Rev Gastroenterol Disord 2004; 4 Suppl 2: S43-S51
12. Degen L, Matzinger D, Merz M, Appel-Dingemanse S, Maecke H, Beglinger C. Tegaserod (HTF 919), a 5-HT4 receptor partial agonist, accelerates gastrointestinal (GI) tract. Neurogastroenterol Motil 2000; 12: 382
13. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000; 118: 463-468
14. Johanson JF, Wald A, Tougas G, Chey WD, Novick JS, Lembo AJ, Fordham F, Guella M, Nault B. Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial. Clin Gastroenterol Hepatol 2004; 2: 796-805
15. Kamm MA, Muller-Lissner S, Talley NJ, Tack J, Boeckxstaens G, Minushkin ON, Kalinin A, Dzieniszewski J, Haeck P, Fordham F, Hugot-Cournez S, Nault B. Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study. Am J Gastroenterol 2005; 100: 362-372
16. Muller-Lissner SA, Fumagalli I, Bardhan KD, Pace F, Pecher E, Nault B, Ruegg P. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001; 15: 1655-1666
17. Novick J, Miner P, Krause R, Glebas K, Bliesath H, Ligozio G, Ruegg P, Lefkowitz M. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002; 16: 1877-1888
18. Tack J, Muller-Lissner S, Bytzer P, Corinaldesi R, Chang L, Viegas A, Schnekenbuehl S, Dunger-Baldauf C, Rueegg P. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut 2005; 54: 1707-1713
19. O'Donnell LJ, Virjee J, Heaton KW. Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate. BMJ 1990; 300: 439-440
20. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480-1491
21. Muller-Lissner SA, Kamm MA, Scarpignato C, Wald A. Myths and misconceptions about chronic constipation. Am J Gastroenterol 2005; 100: 232-242